Vol. 29 No. 1 (2025)
ANESTHESIOLOGY & RESUSCITATION

The use of exogenous phosphocreatine in surgical correction of valvular heart defects under cardiopulmonary bypass: a randomized, double-blind, placebo-controlled pilot study

PDF (Русский)
  • V.A. Boboshko,
  • P.P. Perovskiy,
  • V.N. Lomivorotov,
  • A.N. Shilova,
  • A.S. Zalesov,
  • V.A. Nepomnyashchikh,
  • V.Ya. Martynenkov,
  • A.M. Chernyavskiy
V.A. Boboshko
Meshalkin National Medical Research Center, Ministry of Health of Russian Federation, Novosibirsk
Bio
P.P. Perovskiy
Meshalkin National Medical Research Center, Ministry of Health of Russian Federation, Novosibirsk
V.N. Lomivorotov
Meshalkin National Medical Research Center, Ministry of Health of Russian Federation, Novosibirsk
A.N. Shilova
Meshalkin National Medical Research Center, Ministry of Health of Russian Federation, Novosibirsk
A.S. Zalesov
Meshalkin National Medical Research Center, Ministry of Health of Russian Federation, Novosibirsk
V.A. Nepomnyashchikh
Meshalkin National Medical Research Center, Ministry of Health of Russian Federation, Novosibirsk
V.Ya. Martynenkov
Meshalkin National Medical Research Center, Ministry of Health of Russian Federation, Novosibirsk
A.M. Chernyavskiy
Meshalkin National Medical Research Center, Ministry of Health of Russian Federation, Novosibirsk; Novosibirsk State Medical University, Ministry of Health of the Russian Federation, Novosibirsk
DOI: https://doi.org/10.21688/1681-3472-2025-1-31-46

Published 2025-04-28

Keywords

  • Cardioplegia,
  • Cardiopulmonary Bypass,
  • Myocardial Protection,
  • Phosphocreatine,
  • Valve Cardiac Surgery,
  • Troponin
    • ...More
    Less

How to Cite

Boboshko, V., Perovskiy, P., Lomivorotov, V., Shilova, A., Zalesov, A., Nepomnyashchikh, V., Martynenkov, V., & Chernyavskiy, A. (2025). The use of exogenous phosphocreatine in surgical correction of valvular heart defects under cardiopulmonary bypass: a randomized, double-blind, placebo-controlled pilot study. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 29(1), 31–46. https://doi.org/10.21688/1681-3472-2025-1-31-46

Copyright (c) 2025 Boboshko V.A., Perovskiy P.P., Lomivorotov V.N., Shilova A.N., Zalesov A.S., Nepomnyashchikh V.A., Martynenkov V.Ya., Chernyavskiy A.M.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Introduction: Myocardial ischemia and stunning during cardiac surgery remain a common and serious complication of the perioperative period with a significant negative impact on patient outcomes, especially in high-risk patients. Experimental and clinical studies have demonstrated that the administration of exogenous phosphocreatine can reduce mortality in patients with coronary artery disease, chronic heart failure, and after heart surgery.

Objective: The study aimed to evaluate the efficacy and safety of using exogenous phosphocreatine in patients scheduled for multivalvular correction under cardiopulmonary bypass.

Methods: A randomized, double-blind, placebo-controlled pilot study enrolled 139 patients scheduled for cardiac surgery, namely plastic/prosthetic replacement of 2 or 3 heart valves under cardiopulmonary bypass. The study group (n = 67) received phosphocreatine according to a specific regimen: 2 grams intravenously after induction of anesthesia, 2.5 grams as part of the cardioplegia solution, 2 grams after restoration of heart rhythm, and 4 grams upon admission to the intensive care unit (ICU). The control group (n = 72) received an equal volume of saline. The primary outcome measure was the concentration of troponin I on the first postoperative day. Secondary endpoints included the following indicators: hemodynamic data (cardiac index, pulmonary artery pressure and pulmonary capillary wedge pressure), the number of patients who required vasopressor or inotropic support, the vasoinotropic index, the duration of artificial ventilation, the frequency of acute kidney injury, the frequency of atrial fibrillation, the duration of stay in the ICU, hospitalization time, 30-day mortality, and long-term survival over three years.

Results: Troponin I levels on the first postoperative day did not differ significantly between the groups and amounted to 9768.3 (6350.6–16486.6) pg/ml in the placebo group and 12156.3 (6696.8–20976.7) pg/ml in the study group, p = 0.292). There were also no significant differences in hemodynamic data throughout the study. The number of patients who required inotropic and vasopressor support was similar between the two groups: 64 (88.9%) patients in the placebo group and 59 (88.1%) patients in the study group, p = 0.695. Cardiac index 1.26 L/(min∙m²) was a predictor of the need for renal replacement therapy with a sensitivity of 100% and specificity of 93% (an AUC of 0.96 (p = 0.005)). The mean pulmonary artery pressure value of 24 mmHg was a predictor for the development of renal dysfunction, with a sensitivity of 92% and specificity of 52% (AUC = 0.78; p = 0.002). In univariate regression analysis, several factors independently influenced the need for inotropic support in the early postoperative period: CPB (cardiopulmonary bypass) duration (for 10 min OR = 1.57; 95% CI 1.11–2.44, р = 0.007) and troponin I levels in 6 h after CPB (for 5000 pg/ml OR = 1.33; 95% CI 1.05–1.86, p = 0.016). Long-term survival over 3 years after surgery was similar between the study groups (HR 1.10; 95% CI 0.35–3.40, p = 0.873).

Conclusion: Administration of exogenous phosphocreatine to patients undergoing operations on 2 or 3 heart valves under cardiopulmonary bypass is safe, but does not have an additional cardioprotective effect. Exogenous phosphocreatine does not have a positive effect on clinical outcomes and long-term survival (3 years) in this category of patients

Received 19 November 2024. Revised 20 February 2025. Accepted 24 February 2025.

Funding
The study did not have sponsorship.

Conflict of interest
The authors declare no conflict of interest.

Contribution of the authors
Conception and study design: V.A. Boboshko, V.N. Lomivorotov
Data collection and analysis: V.A. Boboshko, A.N. Shilova, A.S. Zalesov
Statistical analysis: P.P. Perovskiy
Drafting the article: V.A. Boboshko, V.A. Nepomnyashchikh, P.P. Perovskiy
Critical revision of the article: V.Ya. Martynenkov, A.M. Chernyavskiy
Final approval of the version to be published: V.A. Boboshko, P.P. Perovskiy, V.N. Lomivorotov, A.N. Shilova, A.S. Zalesov, V.A. Nepomnyashchikh, V.Ya. Martynenkov, A.M. Chernyavskiy

PDF (Русский)

References

  1. Fellahi J.L., Gué X., Richomme X., Monier E., Guillou L., Riou B. Short- and long-term prognostic value of postoperative cardiac troponin I concentration in patients undergoing coronary artery bypass grafting. Anesthesiology. 2003;99(2):270-274. PMID: 12883398. https://doi.org/10.1097/00000542-200308000-00007
  2. Croal B.L., Hillis G.S., Gibson P.H., Fazal M.T., El-Shafei H., Gibson G., Jeffrey R.R., Buchan K.G., West D., Cuthbertson B.H. Relationship between postoperative cardiac troponin I levels and outcome of cardiac surgery. Circulation. 2006;114(14):1468-1475. PMID: 17000912. https://doi.org/10.1161/CIRCULATIONAHA.105.602370
  3. Lurati Buse G.A., Koller M.T., Grapow M., Bolliger D., Seeberger M., Filipovic M. The prognostic value of troponin release after adult cardiac surgery — a meta-analysis. Eur J Cardiothorac Surg. 2010;37(2):399-406. PMID: 19699102. https://doi.org/10.1016/j.ejcts.2009.05.054
  4. Kitzenberg D., Colgan S.P., Glover L.E. Creatine kinase in ischemic and inflammatory disorders. Clin Transl Med. 2016;5(1):31. PMID: 27527620; PMCID: PMC4987751. https://doi.org/10.1186/s40169-016-0114-5
  5. Nascimben L., Ingwall J.S., Pauletto P., Friedrich J., Gwathmey J.K., Saks V., Pessina A.C., Allen P.D. Creatine kinase system in failing and nonfailing human myocardium. Circulation. 1996;94(8):1894-1901. PMID: 8873665. https://doi.org/10.1161/01.cir.94.8.1894
  6. Clarke K., O’Connor A.J., Willis R.J. Temporal relation between energy metabolism and myocardial function during ischemia and reperfusion. Am J Physiol. 1987;253(2 Pt 2):H412-H421. PMID: 3618814. https://doi.org/10.1152/ajpheart.1987.253.2.H412
  7. Bessman S.P. The creatine phosphate energy shuttle — the molecular asymmetry of a “pool”. Anal Biochem. 1987;161(2):519-523. PMID: 3578809. https://doi.org/10.1016/0003-2697(87)90483-0
  8. Bessman S.P., Carpenter C.L. The creatine-creatine phosphate energy shuttle. Annu Rev Biochem. 1985;54:831-862. PMID: 3896131. https://doi.org/10.1146/annurev.bi.54.070185.004151
  9. Lygate C.A., Bohl S., ten Hove M., Faller K.M., Ostrowski P.J., Zervou S., Medway D.J., Aksentijevic D., Sebag-Montefiore L., Wallis J., Clarke K., Watkins H., Schneider J.E., Neubauer S. Moderate elevation of intracellular creatine by targeting the creatine transporter protects mice from acute myocardial infarction. Cardiovasc Res. 2012;96(3):466-475. PMID: 22915766; PMCID: PMC3500046. https://doi.org/10.1093/cvr/cvs272
  10. Thelin S., Hultman J., Ronquist G., Juhlin C., Hansson H.E., Lindgren P.G. Improved myocardial protection by creatine phosphate in cardioplegic solution. An in vivo study in the pig during normothermic ischemia. Thorac Cardiovasc Surg. 1987;35(3):137-142. PMID: 2442831. https://doi.org/10.1055/s-2007-1020217
  11. Spindler M., Meyer K., Strömer H., Leupold A., Boehm E., Wagner H., Neubauer S. Creatine kinase-deficient hearts exhibit increased susceptibility to ischemia-reperfusion injury and impaired calcium homeostasis. Am J Physiol Heart Circ Physiol. 2004;287(3):H1039-H1045. PMID: 15105171. https://doi.org/10.1152/ajpheart.01016.2003
  12. ten Hove M., Lygate C.A., Fischer A., Schneider J.E., Sang A.E., Hulbert K., Sebag-Montefiore L., Watkins H., Clarke K., Isbrandt D., Wallis J., Neubauer S. Reduced inotropic reserve and increased susceptibility to cardiac ischemia/reperfusion injury in phosphocreatine-deficient guanidinoacetate-N-methyltransferase-knockout mice. Circulation. 2005;111(19):2477-2485. PMID: 15883212. https://doi.org/10.1161/01.CIR.0000165147.99592.01
  13. Жидков И.Л., Иванов В.А., Кожевников В.В., Чарная М.А., Мухамедзянова А.Р., Трекова Н.А. Интраоперационная защита миокарда внеклеточными кардиоплегическими растворами у пациентов с патологией клапанов сердца. Анестезиология и реаниматология. 2007;23(2):38-42. Zhidkov I.L., Ivanov V.A., Kozhevnikov V.A., Charnaya M.A., Mukhamedzyanova A.R., Trekova N.A. Intraoperative myocardial protection with extracellular cardioplegic solutions in patients with cardiac valve diseases. Russian Journal of Anesthesiology and Reanimatology. 2007;23(2):38-42. (In Russ.) PMID: 17563998.
  14. Ковалев С.А., Белов В.Н., Осипова О.А. Эффективность фосфокреатина у больных ишемической болезнью сердца и сердечной недостаточностью после хирургической реваскуляризации миокарда. Вестник экспериментальной и клинической хирургии. 2015;8(4):314-317. Kovalev S.A., Belov V.N., Osipova O.A. The effectiveness of phosphocreatine in patients with ischemic heart disease and heart failure after surgical revascularization. Journal of Experimental and Clinical Surgery. 2015;8(4):314-317. (In Russ.)
  15. Шестакова Л.Г. Кардиопротекторная эффективность экзогенного фосфокреатина после глобальной ишемии при операциях на открытом сердце у пациентов со сниженной фракцией выброса левого желудочка: сравнительное исследование. Кардиология в Беларуси. 2023;15(1):58-70. https://doi.org/10.34883/PI.2023.15.1.012 Shestakova L.G. Cardioprotective efficacy of exogenous phosphocreatine after global ischemia in open heart surgery in patients with reduced left ventricular ejection fraction: a comparative study. Cardiology in Belarus. 2023;15(1):58-70. (In Russ.) https://doi.org/10.34883/PI.2023.15.1.012
  16. Малыгин А.С., Демидова М.А., Ломиворотов В.В. Сравнительная клинико-экономическая оценка применения фосфокреатина (Неотона) при кардиохирургических вмешательствах с искусственным кровообращением. Клиническая фармакология и терапия. 2018;27(1):83-89. Malygin A.S., Demidova M.A., Lomivorotov V.V. Comparative clinical and economic evaluation of phosphocreatine (Neoton) administration during cardiac surgery with extracorporeal ciculation. Clinical Pharmacology and Therapy. 2018;27(1):83-89. (In Russ.)
  17. Landoni G., Zangrillo A., Lomivorotov V.V., Likhvantsev V., Ma J., De Simone F., Fominskiy E. Cardiac protection with phosphocreatine: a meta-analysis. Interact Cardiovasc Thorac Surg. 2016;23(4):637-646. PMID: 27318357. https://doi.org/10.1093/icvts/ivw171
  18. Mingxing F., Landoni G., Zangrillo A., Monaco F., Lomivorotov V.V., Hui C., Novikov M., Nepomniashchikh V., Fominskiy E. Phosphocreatine in cardiac surgery patients: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth. 2018;32(2):762-770. PMID: 29409711. https://doi.org/10.1053/j.jvca.2017.07.024
  19. Belletti A., Lerose C.C., Zangrillo A., Landoni G. Vasoactive-inotropic score: evolution, clinical utility, and pitfalls. J Cardiothorac Vasc Anesth. 2021;35(10):3067-3077. PMID: 33069558. https://doi.org/10.1053/j.jvca.2020.09.117
  20. Ueno K., Shiokawa N., Takahashi Y., Nakae K., Kawamura J., Imoto Y., Kawano Y. Kidney Disease: Improving Global Outcomes in neonates with acute kidney injury after cardiac surgery. Clin Exp Nephrol. 2020;24(2):167-173. PMID: 31677063. https://doi.org/10.1007/s10157-019-01805-7
  21. Marshall R.J., Parratt J.R. Reduction in ventricular arrhythmias following acute coronary artery ligation in the dog after the administration of creatine phosphate. Naunyn Schmiedebergs Arch Pharmacol. 1974;281(4):437-441. PMID: 4275263. https://doi.org/10.1007/BF00499438
  22. Semenovsky M.L., Shumakov V.I., Sharov V.G., Mogilevsky G.M., Asmolovsky A.V., Makhotina L.A., Saks V.A. Protection of ischemic myocardium by exogenous phosphocreatine. II. Clinical, ultrastructural, and biochemical evaluations. J Thorac Cardiovasc Surg. 1987;94(5):762-769. PMID: 3312824.
  23. Бараев О.В., Зотов А.С., Ильин М.В., Смирнова В.П., Цыбин Н.В. Результаты применения экзогенного креатинфосфата при операциях аортокоронарного шунтирования с экстракорпоральным кровообращением у пациентов со сниженными резервами миокарда. Вестник Национального медико-хирургического Центра им. Н.И. Пирогова. 2012;7(4):25-28. Barayev O.V., Zotov A.S., Ilyin M.V., Smirnova V.P., Tsybin N.V. Results of exogenous phosphocreatine use in coronary artery bypass surgery using extracorporeal circulation system in patients with reduced myocardial flow reserves. Vestnik Natsionalnogo mediko-khirurgicheskogo Tsentra imeni N.I. Pirogova = Bulletin of Pirogov National Medical & Surgical Center. 2012;7(4):25-28. (In Russ.)
  24. Xiao-qian D. Effect of creatine phosphate on myocardial ischemia-reperfusion in type 2 diabetic patients undergoing cardiac valve replacement. The Journal of Clinical Anesthesiology. 2015;(1):9-11.
  25. Hu-shan A., Jian-lin S., Chang-ying L. Effect of large dose creatine phosphate on myocardial ischemia-reperfusion injury in patients undergoing cardiac valve replacement. Chinese Journal of Anesthesiology. 2010;30:344-346.
  26. Thorelius J., Thelin S., Ronquist G., Halden E., Hansson H.E. Biochemical and functional effects of creatine phosphate in cardioplegic solution during aortic valve surgery — a clinical study. Thorac Cardiovasc Surg. 1992;40(1):10-13. PMID: 1631861. https://doi.org/10.1055/s-2007-1020103
  27. Cheng S.X., Hu Q.H. Cardioprotective effect of exogenous phosphocreatine in patients undergoing open heart surgery. Hunan Yi Ke Da Xue Xue Bao. 2001;26:353-355. PMID: 12536735.
  28. Guo-han C., Jian-hua G., Xuan H., Jinyi W., Rong L., Zhong-min L. Role of creatine phosphate as a myoprotective agent during coronary artery bypass graft in elderly patients. Coron Artery Dis. 2013;24(1):48-53. PMID: 23114287. https://doi.org/10.1097/MCA.0b013e32835aab95
  29. Tevaearai Stahel H.T., Do P.D., Klaus J.B., Gahl B., Locca D., Göber V., Carrel T.P. Clinical relevance of troponin T profile following cardiac surgery. Front Cardiovasc Med. 2018;5:182. PMID: 30619889; PMCID: PMC6301188. https://doi.org/10.3389/fcvm.2018.00182
  30. Gaudino M., Pragliola C., Anselmi A., Pieroni M., De Paulis S., Leone A., De Caterina A.R., Massetti M. Randomized trial of HTK versus warm blood cardioplegia for right ventricular protection in mitral surgery. Scand Cardiovasc J. 2013;47(6):359-367. PMID: 24053647. https://doi.org/10.3109/14017431.2013.836241
  31. Lomivorotov V., Merekin D., Fominskiy E., Ponomarev D., Bogachev-Prokophiev A., Zalesov A., Cherniavsky A., Shilova A., Guvakov D., Lomivorotova L., Lembo R., Landoni G. Myocardial protection with phosphocreatine in high-risk cardiac surgery patients: a randomized trial. BMC Anesthesiol. 2023;23(1):389. PMID: 38030971; PMCID: PMC10685505. https://doi.org/10.1186/s12871-023-02341-4
  32. Ad N., Henry L., Massimiano P., Pritchard G., Holmes S.D. The state of surgical ablation for atrial fibrillation in patients with mitral valve disease. Curr Opin Cardiol. 2013;28(2):170-180. PMID: 23295553. https://doi.org/10.1097/HCO.0b013e32835ced9c
  33. Rudolph T.K., Messika-Zeitoun D., Frey N., Thambyrajah J., Serra A., Schulz E., Maly J., Aiello M., Lloyd G., Bortone A.S., Clerici A., Delle-Karth G., Rieber J., Indolfi C., Mancone M., Belle L., Lauten A., Arnold M., Bouma B.J., Lutz M., Steeds R.P. Impact of selected comorbidities on the presentation and management of aortic stenosis. Open Heart. 2020;7(2):e001271. PMID: 32709699; PMCID: PMC7380845. https://doi.org/10.1136/openhrt-2020-001271
  34. Gillinov M., Moskowitz A.J., Argenziano M. Surgical ablation for atrial fibrillation. New Engl J Med. 2015;373(5):484. PMID: 26222570. https://doi.org/10.1056/NEJMc1506893
  35. Богачев-Прокофьев А.В., Сапегин А.В., Пивкин А.Н., Шарифулин Р.М., Афанасьев А.В., Овчаров М.А., Караськов А.М. Среднеотдаленные результаты профилактической аблации предсердий у пациентов с пороками митрального клапана и атриомегалией: пилотное рандомизированное исследование. Патология кровообращения и кардио­хирургия. 2017;21(2):98-107. https://doi.org/10.21688/1681-3472-2017-2-98-107 Bogachev-Prokophiev A.V., Sapegin A.V., Pivkin A.N., Sharifulin R.M., Afanasyev A.V., Ovcharov M.A., Karaskov A.M. Preventive AF ablation in patients with mitral valve lesion and left atrium enlargement: 3-month follow-up results. Patologiya krovoobrashcheniya i kardiokhirurgiya = Circulation Pathology and Cardiac Surgery. 2017;21(2):98-107. (In Russ.) https://doi.org/10.21688/1681-3472-2017-2-98-107
  36. Железнев С.И., Богачев-Прокофьев А.В., Емешкин М.И., Караськов А.М. Отдаленные результаты хирургического лечения фибрилляции предсердий у больных с приобретенными пороками митрального клапана. Патология кровообращения и кардиохирургия. 2014;18(1):5-10. https://doi.org/10.21688/1681-3472-2014-1-5-10 Zheleznev S.I., Bogachev-Prokofiev A.V., Yemeshkin M.I., Karaskov A.M. Long-term results of surgical treatment of atrial fibrillation in patients with mitral valve disease. Patologiya krovoobrashcheniya i kardiokhirurgiya = Circulation Pathology and Cardiac Surgery. 2014;18(1):5-10. (In Russ.) https://doi.org/10.21688/1681-3472-2014-1-5-10
  37. Royster R.L., Butterworth J.F. 4th, Prough D.S., Johnston W.E., Thomas J.L., Hogan P.E., Case L.D., Gravlee G.P. Preoperative and intraoperative predictors of inotropic support and long-term outcome in patients having coronary artery bypass grafting. Anesth Analg. 1991;72(6):729-736. PMID: 1827965. https://doi.org/10.1213/00000539-199106000-00002
  38. Яновская И.М., Мандель И.А., Клыпа Т.В., Колышкина Н.А., Марей И.С., Зотов А.С., Баклаушев В.П. Диагностическая значимость высокочувствительных тропонинов в кардиохирургии. Клиническая практика. 2022;13(3):32-42. https://doi.org/10.17816/clinpract111002 Yanovskaya I.M., Mandel I.A., Klypa T.V., Kolyshkina N.A., Marei I.S., Zotov A.S., Baklaushev V.P. Diagnostic significance of highly sensitive troponins in cardiac surgery. Journal of Clinical Practice. 2022;13(3):32-42. (In Russ.) https://doi.org/10.17816/clinpract111002
  39. Pieri M., Belletti A., Monaco F., Pisano A., Musu M., Dalessandro V., Monti G., Finco G., Zangrillo A., Landoni G. Outcome of cardiac surgery in patients with low preoperative ejection fraction. BMC Anesthesiol. 2016;16(1):97. PMID: 27760527; PMCID: PMC5069974. https://doi.org/10.1186/s12871-016-0271-5
  40. Borde D.P., Asegaonkar B., Khade S., Puranik M., George A., Joshi S. Impact of preoperative pulmonary arterial hypertension on early and late outcomes in patients undergoing valve surgery for rheumatic heart disease. Indian J Anaesth. 2018;62(12):963-971. PMID: 30636798; PMCID: PMC6299764. https://doi.org/10.4103/ija.IJA_374_18
  41. Терещенко С.Н., Черемисина И.А., Сафиуллина А.А. Эффективность неотона у больных с хронической сердечной недостаточностью в зависимости от фракции выброса левого желудочка. Субанализ исследования BYHEART. Российский кардиологический журнал. 2022;27(11):5276. https://doi.org/10.15829/1560-4071-2022-5276 Tereshchenko S.N., Cheremisina I.A., Safiullina A.A. Effectiveness of neoton in patients with chronic heart failure depending on the left ventricular ejection fraction. Sub-analysis of the BYHEART study. Russian Journal of Cardiology. 2022;27(11):5276. (In Russ.) https://doi.org/10.15829/1560-4071-2022-5276
  42. Liu K., Ye Q., Zhao Y., Zhao C., Song L., Wang J. Sex differences in the outcomes of degenerative mitral valve repair. Ann Thorac Cardiovasc Surg. 2023;29(4):192-199. PMID: 36908120; PMCID: PMC10466113. https://doi.org/10.5761/atcs.oa.22-00210
  43. Hamed O., Persson P.J., Engel A.M., McDonough S., Smith J.M. Gender differences in outcomes following aortic valve replacement surgery. Int J Surg. 2009;7(3):214-217. PMID: 19332158. https://doi.org/10.1016/j.ijsu.2009.03.005